4-arylquinazoline MAT2A Inhibitors for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies like chemotherapy and immunotherapy have cytotoxic effects that are not specific to cancer cells, leading to adverse side effects in normal tissues, necessitating novel strategies to target cancer cells more effectively.
Innovation Solution
Development of 4-arylquinazoline derivatives that inhibit methionine adenosyltransferase 2A (MAT2A), specifically designed to target cancer cells with reduced or absent methylthioadenosine phosphorylase (MTAP) activity, thereby disrupting S-adenosyl methionine synthesis essential for cancer cell survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy and immunotherapy are used to treat cancer, then cancer cells can be targeted, but normal tissues are also damaged causing adverse side effects
Solution Approach 1:
The patent applies local quality by designing MAT2A inhibitors with specific molecular structures (4-arylquinazoline derivatives) that selectively bind to the MAT2A enzyme. This selective binding ensures the drug acts locally on cancer cells expressing MAT2A while sparing normal cells, thereby improving targeting specificity and reducing side effects in normal tissues.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the differential expression levels of MAT2A between cancer cells and normal cells. Cancer cells typically overexpress MAT2A, creating a parameter difference that the inhibitors exploit to achieve selective toxicity. By targeting this specific parameter (MAT2A expression level), the therapy achieves better specificity and reduced harm to normal tissues.
2Reliability
If MAT2A inhibitors are used to selectively target cancer cells, then cancer cell viability is reduced, but selective targeting mechanism must be established
Solution Approach 1:
The patent applies self-service by designing MAT2A inhibitors that exploit the cancer cells' own overexpression of MAT2A against them. The cancer cells' high MAT2A expression, which supports their survival and proliferation, becomes the mechanism for their selective destruction. The drug structure (4-arylquinazoline derivatives) is designed to fit the MAT2A active site, allowing the system to use the target's own characteristics for selective inhibition without requiring complex external targeting mechanisms.
Data Source
AI summary
Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.